论文部分内容阅读
目的:探讨凋亡抑制因子Clusterin在乳腺癌组织中的表达及临床意义。方法:应用免疫组织化学法检测60例乳腺癌、10例乳腺良性病变和10例乳腺正常组织中Clusterin的表达情况,并探讨Cluslerin表达与乳腺癌各临床病理学参数间的关系。结果:Clusterin在乳腺正常组织、乳腺良性病变及乳腺癌组织中的阳性表达率分别为0%、10%及78_33%,乳腺癌组织中的Clusterin表达水平明显高于乳腺良性病变及乳腺正常组织(均P<0.01);Clusterin在乳腺癌中的表达与组织学分级、淋巴结转移相关(P<0.05),与年龄、肿瘤直径及临床分期无关;在乳腺癌组织中Cluslerin与ER、PR的表达负相关,与C-erbB-2的表达无明显相关,与p53、Ki67的表达呈正相关。结论:Clusterin可能通过抑制细胞凋亡在乳腺癌的发生发展中发挥重要作用,并有可能成乳腺癌治疗的新靶点。
Objective: To investigate the expression of Clusterin in breast cancer and its clinical significance. Methods: The expressions of Clusterin in 60 cases of breast cancer, 10 cases of benign breast lesions and 10 cases of normal breast tissues were detected by immunohistochemistry. The relationship between Cluslerin expression and clinicopathological parameters of breast cancer was also explored. Results: The positive rates of Clusterin in normal breast tissues, benign breast lesions and breast cancer tissues were 0%, 10% and 78_33% respectively. The expression of Clusterin in breast cancer tissues was significantly higher than that in benign breast lesions and normal breast tissues P <0.01). The expression of Clusterin in breast cancer was correlated with histological grade and lymph node metastasis (P <0.05), but not with age, tumor diameter and clinical stage. The expression of Cluslerin, ER and PR in breast cancer tissues was negative Correlation with the expression of C-erbB-2 was not significantly correlated with the expression of p53, Ki67 was positively correlated. Conclusion: Clusterin may play an important role in the development of breast cancer by inhibiting apoptosis, and may be a new target for the treatment of breast cancer.